Ley D, Mühl-Benninghaus R, Yilmaz U, Körner H, Cattaneo G F M, Mailänder W, Kim Y-J, Scheller B, Reith W, Simgen A
Departments of Neuroradiology, Saarland University Hospital, Kirrbergerstraße1, 66424, Homburg/Saar, Germany.
Acandis GmbH, Pforzheim, Germany.
Clin Neuroradiol. 2017 Sep;27(3):335-343. doi: 10.1007/s00062-015-0493-9. Epub 2015 Dec 23.
In recent years, flow diverters have provided a promising alternative to treat complex intracranial aneurysms. In this study, we compare a second-generation flow-diverting device (Derivo Embolization Device) with its prototype flow diverter, in the treatment of elastase-induced aneurysms in New Zealand white rabbits.
The Derivo Embolization Device is a self-expanding stent consisting of 48 nitinol wires. The device was implanted across the necks of 17 elastase-induced aneurysms in New Zealand white rabbits. One additional device was implanted in the abdominal aorta of each animal covering the origin of lumbar arteries. Follow-up was performed after 3 months (n = 8) and 6 months (n = 9) under continuous double antiplatelet therapy. Statuses of angiographic and histological aneurysm occlusion as well as patency of branch arteries and neointimal growth were evaluated and compared with its prototype flow diverter.
The Derivo Embolization Device provided advanced visibility and flexibility, which led to more accurate navigation and placement. Complete aneurysm occlusion rates were noted in 15 cases (88 %), respectively, compared with 5 cases (28 %) with the first-generation device (p = 0.001). Neointimal growth and diameter stenosis were significantly less with the Derivo Embolization Device and declining after 6 months follow-up in the abdominal aorta. Extreme device oversizing led to distal occlusion of the parent vessel in three cases. Covered branch arteries remained patent throughout the entire period of observation.
The Derivo Embolization Device provides excellent occlusion of elastase-induced aneurysms while preserving branch arteries.
近年来,血流导向装置为治疗复杂颅内动脉瘤提供了一种有前景的替代方法。在本研究中,我们比较了第二代血流导向装置(Derivo栓塞装置)与其原型血流导向装置在治疗新西兰白兔弹性蛋白酶诱导的动脉瘤中的效果。
Derivo栓塞装置是一种由48根镍钛诺丝组成的自膨胀支架。该装置被植入17只新西兰白兔弹性蛋白酶诱导的动脉瘤颈部。每只动物的腹主动脉还植入了一个额外的装置,覆盖腰动脉起源处。在持续双重抗血小板治疗下,分别于3个月(n = 8)和6个月(n = 9)进行随访。评估并比较了血管造影和组织学上动脉瘤闭塞的状态以及分支动脉的通畅情况和新生内膜生长情况,并与其原型血流导向装置进行比较。
Derivo栓塞装置具有更好的可视性和灵活性,从而实现了更精确的导航和放置。分别有15例(88%)实现了完全动脉瘤闭塞,而第一代装置为5例(28%)(p = 0.001)。Derivo栓塞装置的新生内膜生长和直径狭窄明显较少,且在腹主动脉随访6个月后有所下降。极端的装置尺寸过大导致3例出现母血管远端闭塞。在整个观察期内,被覆盖的分支动脉保持通畅。
Derivo栓塞装置在保留分支动脉的同时,能出色地闭塞弹性蛋白酶诱导的动脉瘤。